GlaxoSmithKline

🇬🇧United Kingdom

Country: 🇬🇧United Kingdom

Ownership: Public

Established: 1929-01-01

Employees: 70.2K

Market Cap: $90B

Website: http://www.gsk.com

Introduction: GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Clinical Trials

A Single Dose Of Compound SB-681323 Compared To Prednisolone On A Protein That Is an Indicator For Rheumatoid Arthritis

Phase 2

Completed

Conditions: Arthritis, Rheumatoid

First Posted Date: 2005-08-25

Last Posted Date: 2017-07-31

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 77

Registration Number: NCT00134693

Locations: 🇬🇧
GSK Investigational Site, Sheffield, United Kingdom

Topical SB-275833 Ointment, 1% For The Treatment Of Impetigo

Phase 3

Completed

Conditions: Skin Infections, Bacterial

First Posted Date: 2005-08-24

Last Posted Date: 2017-01-23

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 520

Registration Number: NCT00133874

Locations: 🇿🇦
GSK Investigational Site, Pretoria, South Africa

Treatment Of Impetigo With Topical SB-275833 Ointment, 1% Versus Topical Placebo Ointment

Phase 3

Completed

Conditions: Impetigo

First Posted Date: 2005-08-24

Last Posted Date: 2016-09-23

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 210

Registration Number: NCT00133848

Locations: 🇵🇪
GSK Investigational Site, Lima, Peru

3 Formulations of Hib-MenCY-TT Vaccine & 1 Formulation of Hib-MenC-TT Vaccine Compared to Licensed Meningococcal Serogroup C Conjugate Vaccine, Each Administered at 2,3,4 Mths of Age

Phase 2

Completed

Conditions: Haemophilus Influenzae Type b
Neisseria Meningitidis

Interventions: Biological: Hib-MenCY-TT vaccine
Biological: Hib-MenC-TT vaccine
Biological: Menjugate ®
Biological: Infanrix penta ®
Biological: Infanrix hexa ®

First Posted Date: 2005-08-11

Last Posted Date: 2018-08-27

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 388

Registration Number: NCT00129116

Locations: 🇩🇪
GSK Investigational Site, Hamburg, Germany

Comparison of GSKBiologicals' Hib-MenCY-TT Vaccine vs Licensed Hib Conjugate or Meningococcal Vaccine

Phase 2

Completed

Conditions: Haemophilus Influenzae Type b
Neisseria Meningitidis

Interventions: Biological: GSK Biologicals' Haemophilus influenza type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine 792014 vaccine
Biological: Pediarix
Biological: ActHIB
Biological: Menomune
Biological: Prevnar

First Posted Date: 2005-08-11

Last Posted Date: 2018-08-24

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 756

Registration Number: NCT00129129

Locations: 🇺🇸
GSK Investigational Site, Warwick, Rhode Island, United States

Vaccine To Prevent Cervical Intraepithelial Neoplasia or Cervical Cancer in Younger Healthy Participants

Phase 3

Completed

Conditions: Cervical Cancer
Precancerous Condition

Interventions: Biological: hepatitis A inactivated virus vaccine
Biological: human papillomavirus 16/18 L1 virus-like particle/AS04 vaccine

First Posted Date: 2005-08-10

Last Posted Date: 2019-03-08

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 7466

Registration Number: NCT00128661

Locations: 🇨🇷
Proyecto Epidemiologico Guanacaste, Liberia, Costa Rica

Dose Ranging Study of Combined Haemophilus Influenzae Type B-Meningococcal Serogroups CY (Hib-MenCY-TT) Vaccine

Phase 2

Completed

Conditions: Haemophilus Influenzae Type b
Neisseria Meningitidis

Interventions: Biological: Hib-MenCY-TT vaccine (MenHibrix)
Biological: Meningitec®
Biological: ActHIB®
Biological: Prevenar®
Biological: Infanrix® Penta
Biological: Mencevax® ACWY
Biological: PRP (Polyribosyl Ribitol Phosphate)